Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia.

doi:10.31557/APJCP.2026.27.8.2969

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia.

Asian Pacific journal of cancer prevention : APJCP - 1 Aug 2026

Nurhayati Fitri, Andalucia Rizka, Thobari Jarir Ath, Syahruddin Elisna, Anggriani Yusi

Abstract excerpt

BACKGROUND: Gefitinib is standard first-line therapy for $EGFR$-mutated non-small cell lung cancer (NSCLC). Following Indonesia's 2020 transition to generic gefitinib in national procurement, real-world comparative data remain limited. This study compared clinical outcomes between innovator and generic gefitinib in Indonesian referral hospitals. METHODS: We conducted a retrospective cohort study of adults with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Gefitinib

Share to Indonesia

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 42663218
DOI: 10.31557/APJCP.2026.27.8.2969

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.